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AbstrACt
Objective To determine the effectiveness of a web-based 
self-management programme for people with type 2 
diabetes in improving glycaemic control and reducing 
diabetes-related distress.
Methods and design Individually randomised two-arm 
controlled trial.
setting 21 general practices in England.
Participants Adults aged 18 or over with a diagnosis 
of type 2 diabetes registered with participating general 
practices.
Intervention and comparator Usual care plus either 
Healthy Living for People with Diabetes (HeLP-Diabetes), 
an interactive, theoretically informed, web-based self-
management programme or a simple, text-based website 
containing basic information only.
Outcomes and data collection Joint primary outcomes 
were glycated haemoglobin (HbA1c) and diabetes-
related distress, measured by the Problem Areas in 
Diabetes (PAID) scale, collected at 3 and 12 months after 
randomisation, with 12 months the primary outcome point. 
Research nurses, blind to allocation collected clinical data; 
participants completed self-report questionnaires online.
Analysis The analysis compared groups as randomised 
(intention to treat) using a linear mixed effects model, 
adjusted for baseline data with multiple imputation of 
missing values.
results Of the 374 participants randomised between 
September 2013 and December 2014, 185 were 
allocated to the intervention and 189 to the control. Final 
(12 month) follow-up data for HbA1c were available 
for 318 (85%) and for PAID 337 (90%) of participants. 
Of these, 291 (78%) and 321 (86%) responses were 
recorded within the predefined window of 10–14 months. 
Participants in the intervention group had lower HbA1c 
than those in the control (mean difference −0.24%; 95% 
CI −0.44 to −0.049; p=0.014). There was no significant 
overall difference between groups in the mean PAID 
score (p=0.21), but prespecified subgroup analysis of 
participants who had been more recently diagnosed with 
diabetes showed a beneficial impact of the intervention in 
this group (p = 0.004). There were no reported harms.
Conclusions Access to HeLP-Diabetes improved 
glycaemic control over 12 months.
trial registration number  ISRCTN02123133.
IntrOduCtIOn
There is a global epidemic of type 2 diabetes 
mellitus (T2DM). An estimated 422 million 
adults, or 10% of the global population, were 
living with diabetes in 2014 of whom around 
90% had type 2 diabetes.1 Poorly controlled 
diabetes is associated with premature mortality 
and a high risk of complications, including 
cardiovascular disease, nephropathy and reti-
nopathy. The risk of complications can be 
reduced by good control of glycaemia and 
cardiovascular risk factors.2 3 Interventions 
which improve self-management skills for 
patients with diabetes can improve health 
outcomes and reduce healthcare costs4 and 
international guidelines support training 
patients in self-management.3 5 However, it 
is not clear how best to support patients in 
developing such skills, and uptake of diabetes 
self-management education remains low. In 
England, despite over 90% of eligible patients 
strengths and limitations of this study
 ► The trial recruited to target and achieved reasonable 
follow-up; hence, the results for the population of 
participants are robust (internal validity).
 ► The two coprimary outcomes reflected the goals of 
the intervention, namely improving diabetes control 
and reducing diabetes-related distress.
 ► However, despite wide inclusion criteria and a 
deliberately pragmatic design, trial participants 
were well controlled at baseline, and therefore the 
extent to which the trial results generalise to the 
wider population of people with type 2 diabetes is 
open to discussion (external validity).
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being referred,6 only 5.3% attended self-management 
training in 2014–2015.7
Poor uptake may be related to the dominant model 
of structured education, which is group-based sessions, 
lasting a half or whole day or spread over regular sessions 
over several weeks.8 Many patients, such as those who 
work, those with caring commitments or those who are 
uncomfortable in groups, may find it difficult to attend.9 10
Web-based support for self-management could address 
some of these barriers, particularly in high-income coun-
tries, where levels of web access are high. In the UK, 
over 80% of households had internet access in 2015, and 
internet access among older people continues to grow 
steadily.11 12 Potential advantages include convenience, 
anonymity, regular updates and the potential to use 
video and graphics to present complex information in a 
format accessible to those with low literacy.13 Although 
systematic reviews have confirmed that computer-based 
interventions can improve health outcomes in diabetes,14 
not all such interventions have a beneficial impact, with 
meta-analyses showing substantial heterogeneity related 
to widely differing interventions, including in the use of 
theory to develop the intervention,15 outcomes14 16 and 
the duration of follow-up, with most trials having rela-
tively short follow-up (less than 12 months).14 This is 
the first UK-based trial of a comprehensive, web-based 
self-management support programme for people with 
type 2 diabetes.
This trial assessed the effects of a web-based self-man-
agement programme, called Healthy Living for People 
with Diabetes (HeLP-Diabetes), on glycated haemoglobin 
(HbA1c) and diabetes-related distress over 12 months.
MethOds
trial design and participants
 Multicentre, two-arm individually randomised controlled 
trial in 21 general practices in England with a mix of 
urban, suburban and rural practices. Practices were 
required to have two nurses—one to facilitate access to 
the intervention, and one to collect data.
recruitment
Standard opt-in recruitment procedures were followed. 
Each practice had a register of patients with T2DM. The 
electronic medical record of every patient on this register 
was reviewed to screen out ineligible patients, and the 
remainder were sent a letter from their general practi-
tioner (GP), inviting them to participate in the study. 
Eligible participants were adults, aged 18 or over, with 
T2DM, registered with participating general practices. 
Patients were excluded if they were unable to provide 
informed consent; unable to use a computer due to 
severe mental or physical impairment; had insufficient 
spoken or written English to use the intervention (oper-
ationalised as unable to consult without an interpreter); 
were terminally ill with less than 12 months life expec-
tancy; or were currently participating in a trial of an 
alternative self-management programme. Participants 
were not required to have home internet access or prior 
experience of using the internet to participate. Partici-
pants with previous or current experience of self-manage-
ment education were eligible to participate. Recruitment 
took place between September 2013 and December 2014. 
The trial protocol was submitted for publication in June 
2014.17 There were no changes to the methods after the 
protocol was agreed and the start of the trial. Ethical 
approval was obtained from Camden and Islington 
National Research Ethics Service committee, reference 
12/LO/1571.
Patient involvement
Patients were involved in all stages of the study, including 
contributing to the original application for funding as 
coinvestigators; substantive and ongoing contribution to 
intervention development; contributing to the trial design, 
including the decision to have two coprimary outcomes; 
active membership of the Trial Steering Committee and 
Trial Management Group and contributing to the writing 
of this paper. This last role is recognised through coau-
thorship (MK).
randomisation and blinding
Randomisation marked the point of study entry. It was 
performed centrally (independently of the trial team), 
after written informed consent was obtained and all 
baseline data were completed, using a web-based rando-
misation system, at the level of the individual partici-
pant. Randomisation was conducted in a 1:1 ratio using 
random permuted blocks of sizes 2, 4 and 6, stratified 
by recruitment centre. Participants were informed the 
trial compared two forms of web-based support, and 
were blinded as to which was the intervention and which 
the comparator. Nurses who offered facilitation for the 
intervention could not be blinded, but were asked not 
to discuss details of allocation with the nurses who gath-
ered follow-up data. The research team obtaining and 
analysing data from participants were blind to allocation.
Intervention
The intervention consisted of facilitated access to 
HeLP-Diabetes. Facilitation consisted of an introductory 
training session with the practice nurse. In this appoint-
ment, patients were were shown how to log on, set a user 
name and password and introduced to the content of 
the website. HeLP-Diabetes was a theoretically informed 
web-based programme whose overall goals were to 
improve health outcomes and reduce diabetes-related 
distress.18 Overall, content was guided by the Corbin and 
Strauss model of managing a long-term condition which 
posits that patients must undertake medical, emotional 
and role management.19 It was developed using partic-
ipatory design principles, with substantial input from 
users, defined as patients with T2DM and health profes-
sionals caring for such patients. All content was evidence-
based, drawing on evidence on management of diabetes, 
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promoting behaviour change and emotional well-being 
and maximising usability and engagement. Content was 
designed to be accessible to people with a wide range 
of literacy and health literacy skills, with all essential 
content provided in both video and text. There were 
information sections on diabetes, how diabetes is treated, 
possible complications of diabetes, possible impacts of 
diabetes on relationships at home and at work, dealing 
with unusual situations like parties, holidays, travel-
ling or shift work and what lifestyle modifications will 
improve health. There were sections addressing skills and 
behaviour change, including behaviour change modules 
on eating healthily, losing weight, being more physically 
active, smoking cessation, moderating alcohol consump-
tion, managing medicines, glycaemic control and blood 
pressure control. Users could set the programme to send 
themselves reminder text messages or emails, and could 
specify the content and frequency of such reminders. The 
third strand of components focused on emotional well-
being with self-help tools based on cognitive behavioural 
therapy and mindfulness. There were multiple personal 
stories (used with license from health talk online), and 
a moderated forum. Participants were free to use the 
programme as much or as little as they chose. Engage-
ment with the programme was promoted through regular 
newsletters, emails and short message service containing 
updates on latest diabetes-related research or practice, 
seasonally relevant advice (eg, fasting during Ramadan, 
benefits of ‘influenza’ vaccinations), and links to specific 
relevant parts of the programme. Two or three prompts 
were sent each month, although users could opt-out 
of receiving them. Further details are provided in 
online supplementary appendix 1.
Comparator
From a National Health Service (NHS) perspective, the 
important research question was whether the proposed 
intervention could improve health outcomes when 
compared with current practice. However, to improve 
acceptability to participants and to maintain blinding, 
all participants had access to a website. Participants in 
the control arm were given access to a simple informa-
tion website, based on the information available on the 
website of the main UK diabetes charity (Diabetes UK) 
or National Health Service patient information website 
(NHS Choices). They received the same initial facilita-
tion meeting as participants in the intervention group, in 
which they were shown how to log on, set a user name and 
password and how to use the website.
Outcomes and outcome measures
Primary outcomes
The outcomes reflected the dual goals of improving 
health outcomes and reducing diabetes-related distress. 
The two joint primary outcomes were HbA1c and diabe-
tes-related distress, measured by the Problem Areas in 
Diabetes (PAID) scale, both at 12 months postrandomi-
sation. PAID has 20 items focusing on areas that cause 
difficulty for people living with diabetes, including social 
situations, food, friends and family, diabetes treatment, 
relationships with healthcare professionals and social 
support.20 PAID scores range from 0 to 100, with higher 
scores indicating more distress. A score of 40 or more 
indicates significant distress, and around 40% of patients 
with diabetes experience significant distress.21
Secondary outcomes
Clinical secondary outcomes included systolic and 
diastolic blood pressure, body mass index, total choles-
terol and HDL (not fasting), and completion of the ‘nine 
essential processes’ for effective management of diabetes, 
mandated by NHS England (weight, blood pressure, 
smoking status, measurement of serum creatinine, choles-
terol and HbA1c, urinary albumin and assessment of eyes 
and feet) within the previous 12 months.3 Patient-re-
ported outcomes included depression and anxiety, 
measured using the Hospital Anxiety and Depression 
Scale (HADS),22 diabetes-related self-efficacy measured 
using the Diabetes Management Self-Efficacy Scale 
(DMSES),23 and satisfaction with treatment, measured 
using the Diabetes Satisfaction with Treatment Question-
naire status and change version (DTSQs and DTSQc).24
data collection
Data were collected at baseline, 3 and 12 months, with 
12 months the primary endpoint. Patient-reported data 
were collected using online questionnaires emailed to 
participants. Clinical outcomes were collected by nurses 
in participating practices. Participants were asked to 
complete their online questionnaires before visiting the 
nurse for clinical measurements and blood tests. Blood 
samples were analysed at the local NHS laboratory used 
by participating practices for routine clinical analyses. 
Data on completion of the ‘nine essential processes’ were 
collected from the GP record for the 12 months prior 
to randomisation and the 12 months after randomisa-
tion at the 12-month follow-up point to avoid triggering 
behaviour change among the study nurses. Use of the 
intervention was recorded automatically using bespoke 
software that recorded the date, and time of each page 
visited. A new log-in to the intervention was defined as 
any page that was accessed 30 min or more after the last 
accessed page.
sample size calculation
Our original sample size calculation was that randomising 
350 participants with 85% follow-up would provide 90% 
power at the 5% level of significance to detect a 0.25% 
difference in HbA1c and a 4.0 point difference in PAID 
score at 12 months postrandomisation between the 
randomised groups.25 26 Since HbA1c and PAID were joint 
primary outcomes measuring different aspects of T2DM, 
both were tested at a 5% significance level.
Analysis
The analysis followed a prespecified analysis plan, based on 
comparing the groups as randomised (intention-to-treat). 
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The analysis plan was approved by the Trial Steering 
Committee before unblinding and uploaded to the trial 
website (https://www. ucl. ac. uk/ pcph/ research- groups- 
themes/ ehealth/ projects/ projects/ helpdiabetesrct). 
Only HbA1c and PAID measured within 10–14 months 
window period following randomisation was used in 
the primary analysis with missing 12-month outcomes 
multiply imputed using baseline and other outcome 
data (eg, 3 month data and final follow-up data collected 
outside the 10–14 months window). Further information 
on the imputation method is given in online supplemen-
tary appendix 2.
A linear mixed effects model with random centre effects 
was used to analyse each of the primary outcomes sepa-
rately, adjusting for the baseline level of the outcome, age, 
gender, previous participation in other self-management 
programmes, pre-existing cardiovascular disease and time 
since diagnosis of diabetes. Secondary outcome measures 
were analysed similarly using generalised linear mixed 
models, with a normal residual error structure for contin-
uous outcomes and a logit link for the binary outcome 
‘completion of nine essential processes’. Prespecified 
subgroup analysis for the coprimary outcomes was under-
taken by baseline glycaemic control (HbA1c outcome 
only), baseline PAID (PAID outcome only) and dura-
tion of diabetes, treating all potential effect modifiers as 
continuous. The interaction between randomised group 
and each effect modifier was included in the model sepa-
rately and assessed using a Wald test.
Use of the intervention was investigated as a mediator 
for efficacy, using instrumental variable methods, with 
randomisation as the instrument (online supplementary 
figure 1).27 28
Potential contamination was monitored by recording 
participants with similar family names and identifying 
those with the same addresses. Where this occurred, 
it was dealt with in the analysis by reporting the extent 
and undertaking a sensitivity analysis excluding these 
individuals.
A number of other sensitivity analyses were performed 
to assess the robustness of the primary analyses: (1) 
performing two complete case analyses disregarding 
outcomes measured outside 10–14 months and 11–13 
months postrandomisation; (2) repeating the analysis 
using multiple imputation of baseline covariates only; 
(3) fitting linear models excluding centre random effects 
and (4) fitting an unadjusted model using only outcome 
measured in 10–14 months postrandomisation.
The Trial Steering Committee (TSC) took on the role 
of the data monitoring committee. Trial registration 
ISRCTN02123133.
results
Recruitment took place between September 2013 and 
December 2014. An initial 421 patients consented 
to participate, but of these 47 did not fully complete 
their baseline questionnaires and were therefore not 
randomised and did not enter the study. A total of 374 
participants were randomised, of whom 86% (n=321) 
provided data on PAID and 78% (n=291) had HbA1c 
measured within 10 to 14 months of randomisation. 
Additional final outcome data, obtained outside the 
10–14 month predefined window, were available for a 
further 27 participants for HbA1c and 16 participants for 
PAID (figure 1). Data obtained outside the 10–14 months 
window were not used directly in the primary analysis, but 
were entered into the imputation model (online supple-
mentary table 1).
baseline characteristics
Baseline demographic and clinical characteristics are 
shown in table 1. The mean age was nearly 65 years, 
over two-thirds (n=258, 69%) were men and most were 
White British (n=300, 80%). Nearly all (n=370, 99%) had 
a computer with access to the internet at home and just 
over half (n=210, 56%) rated themselves as experienced 
computer users. Around one-third (n=134; 36%) had 
been diagnosed for less than 5 years, with a further third 
(n=115, 31%) having been diagnosed between 5 and 9 
years ago. Overall, this was a population with well-con-
trolled diabetes at baseline (mean HbA1c was 7.3% (56 
mmol/mol)) and low levels of distress (mean PAID=19).
Primary outcomes
At 12 months the primary analysis showed a significant 
difference in change in HbA1c between the randomised 
groups with participants in the HeLP-Diabetes group 
having a lower HbA1c than those in the control group 
(mean difference=−0.24%; 95% CIs −0.44 to −0.049, 
p=0.014) (table 2, figure 2). There was no difference in 
change in PAID scores between the groups at 12 months 
(mean difference −1.5; 95% CI −3.9 to 0.9, p=0.209), 
though both groups showed a decrease in PAID over the 
follow-up of the trial (table 2, figure 3).
secondary outcomes
There was no difference in secondary outcomes at 12 
months, with the possible exception of systolic blood pres-
sure, which decreased more in the intervention group 
than in the control group (p=0.010) (table 2); though 
the result was not statistically significant after correction 
for multiple testing of secondary outcomes. There were 
no significant differences between groups on any of the 
outcome measures among individuals who completed 
3 month outcomes (online supplementary table 2). No 
adverse effects or events were recorded during follow-up.
usage data
The mean number of log-ins was significantly higher in 
the intervention group than the control group (18.7 vs 
4.8, p=0.0001), as was the mean number of pages visited 
per log-in (10.5 vs 7.7, p<0.0001) and the mean number 
of days in which the website was accessed (10.1 vs 3.3, 
p<0.0001) (table 3). The causal analyses estimated that 
for a ‘high-usage’ population (those with usage greater 
than or equal to the median of 4 days) the HeLP-Diabetes 
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intervention could on average reduce HbA1c by −0.44% 
(95% CI −0.81 to −0.06) and PAID by −2.8 (95% CI −7.2 to 
1.7) over 12 months (online supplementary fgures 2 and 
3). The mean usage in the ‘high-usage’ group was 18 days. 
It should be noted that the usage data presented do not 
include the initial facilitation visit. There was a technical 
error in the software which led to usage data not being 
collected before 1 January 2014. At this point 16 partici-
pants had been randomised (seven to intervention, nine 
to control). For these 16 participants, the usage data are 
not based on a full year, but for all other participants, data 
are summarised for the 12 months postrandomisation.
sensitivity analyses
The findings from the sensitivity analyses, including a 
complete-case analysis, were similar to the main anal-
ysis (online supplementary table 3). Participants who 
were missing 12 month HbA1c had significantly higher 
mean baseline HbA1c measures (7.9% vs 7.1%, p<0.001) 
leading to higher imputed HbA1c at 12 months in the 
non-completers and a greater mean difference between 
the randomised groups than from complete case analyses 
(online supplementary figure 4, supplementary table 3).
subgroup analyses
Prespecified subgroup analyses showed that there was no 
evidence of baseline measures of HbA1c or PAID being 
effect modifiers for the mean difference between the 
groups. There was strong statistical evidence (interaction 
p=0.004) to suggest that the duration of diabetes acted as 
an effect modifier, with those who had been diagnosed 
more recently showing more of a reduction in PAID than 
those who had been diagnosed for longer periods of time. 
Duration of diabetes had no effect on change in HbA1c 
(online supplementary table 4).
harms
There were no reported harms in either group.
dIsCussIOn
In this first UK-based trial of a web-based self-manage-
ment programme for people with T2DM, participants 
randomised to HeLP-Diabetes demonstrated improved 
glycaemic control at 12 months compared with those 
randomised to a simple information website. This improve-
ment appears robust across all prespecified sensitivity 
Figure 1 CONSORT diagram showing patient flow through the HeLP-Diabetes randomised controlled trial. HbA1c, glycated 
haemoglobin; HeLP-Diabetes, Healthy Living for People with Diabetes; PAID, Problem Areas in Diabetes.
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analyses, and was not dependent on duration of diabetes, 
baseline glycaemic levels or level of diabetes-related 
distress. Each 1% reduction in HbA1c is associated with a 
risk reduction of 21% for deaths related to diabetes and 
a 37% risk reduction for microvascular complications.26 
A reduction in HbA1c of 0.24% across a population level 
could translate into considerable population benefit, 
particularly as this web-based intervention could be deliv-
ered at low-cost and at scale across the UK. Moreover, 
in contrast to group-based education, where the effects 
Table 1 Descriptive statistics of baseline variables by randomised group
HeLP-Diabetes
n=185
Control
n=189 N missing
Age at randomisation (years) 64.9 (9.5) 64.7 (9.1) 0
Male sex, n (%) 127 (69%) 131 (69%) 0
Ethnicity, n (%) 1
  White English, Welsh, Scottish, Northern Irish, British 151 (82%) 149 (79%)
  Indian 12 (6%) 8 (4%)
  Other 21 (11%) 31 (16%)
Experience with computers, n (%) 0
  None 5 (3%) 4 (2%)
  Basic 75 (41%) 80 (42%)
  Experienced 105 (57%) 105 (56%)
Smoking status, n (%) 0
  Current smoker 14 (8%) 14 (7%)
  Former smoker 94 (51%) 86 (46%)
  Never smoker 77 (42%) 89 (47%)
Time since diagnosis (years), n (%) 4
  0–4 years 70 (38%) 64 (34%)
  5–9 years 55 (30%) 60 (32%)
  10–14 years 40 (22%) 40 (21%)
  15+ years 18 (10%) 23 (12%)
Attending any other self-management class, n (%) 4 (2%) 4 (2%) 0
Clinical measures
Systolic blood pressure (mm Hg) 135 (17) 135 (17) 0
Diastolic blood pressure (mm Hg) 78 (11) 77 (10) 0
Total cholesterol (mmol/L) 4.11 (1.03) 4.18 (0.98) 2
HDL-C (mmol/L) 1.24 (0.31) 1.25 (0.36) 12
Total cholesterol/HDL cholesterol ratio 3.43 (1.09) 3.52 (1.03) 13
HbA1c (%) 7.26 (1.25) 7.35 (1.37) 5
HbA1c (mmol/mol) 56 (14) 57 (15) 5
Body mass index (kg/m2) 30.1 (5.3) 29.6 (5.2) 2
Questionnaires/scores
  PAID (0–100) 18.1 (17.1) 19.9 (19.9) 0
  HADS (0–42) 9.28 (6.47) 9.12 (7.52) 0
   Anxiety scale (0–21) 4.92 (3.70) 5.21 (4.20) 0
   Depression scale (0–21) 4.36 (3.48) 3.91 (3.73) 0
  DMSES (0–150) 98.6 (33.9) 103.7 (32.4) 0
  DTSQ (0–48) 32.1 (7.3) 32.0 (7.2) 0
Completion of nine essential processes in previous 12 months, n (%) 97 (64%) 96 (62%) 69
DMSES, Diabetes Management Self-Efficacy Scale; DTSQ, Diabetes Treatment Satisfaction Questionnaire;  HADS, Hospital Anxiety and 
Depression Scale; HbA1c, glycated haemoglobin;  HDL, high-density lipoprotein; HeLP-Diabetes, Healthy Living for People with Diabetes; 
PAID, Problem Areas in Diabetes.
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appear to wane with time,29 the effects of HeLP-Diabetes 
were greater at 12 months than at 3 months. There was 
no overall impact on diabetes-related distress, but some 
evidence that HeLP-Diabetes appeared to reduce distress 
in recently diagnosed individuals. However, it is worth 
noting that baseline PAID scores were exceptionally low 
in this trial population. In a small pilot study, participants 
offered supported access to HeLP-Diabetes reduced their 
PAID scores by six points (p=0.04) over 6 weeks.30
The trial has many strengths. It was a pragmatic trial, 
open to nearly all patients with T2DM in participating 
practices. Concealment of allocation was complete, as 
randomisation occurred after baseline data collection. 
Baseline prognostic factors were well balanced between 
groups. Every effort was made to achieve blinding, 
including requiring practices to have two nurses, so that 
data collection were undertaken by a nurse blind to 
participant allocation. Data for the coprimary outcomes 
at the primary outcome point were available for 78% and 
86% of participants for HbA1c and PAID, respectively. 
All analyses were on an intention-to-treat basis, supple-
mented by a CACE analysis. Although response rates 
for the coprimary outcomes were good, some poten-
tial for bias existed. Our primary analysis used multiple 
imputation methods because evidence shows that the 
assumptions underpinning this method are more defen-
sible than those assumed using other approaches to 
missing data.31 We also undertook sensitivity analyses 
including complete cases, non-contaminated cases and a 
linear model excluding centre; all yielded similar results.
The two coprimary outcomes reflected the twin aims 
of the intervention: to improve diabetes control and to 
reduce diabetes-related distress. Around 40% of patients 
with diabetes have significant levels of distress, which 
severely impacts on quality of life,32 and diabetes-related 
distress is an important outcome for patients.33 Our 
patient and public involvement panel were clear that this 
should be a primary outcome, and a recent meta-ethnog-
raphy emphasised the importance of empowerment and 
quality of life in promoting long-term engagement with 
self-management.34 In contrast, many healthcare profes-
sionals are more interested in glycaemic control. In line 
with previous trials in this area,35 we decided to adopt 
both as coprimary outcomes and to test both at a 5% level 
of significance.36
There are some limitations. Despite maximising 
the inclusivity of the trial by minimising the exclusion 
criteria, participants were not representative of the overall 
population of patients with type 2 diabetes in England. 
Compared with the overall population, participants had 
Table 2 Twelve-month outcomes, adjusted for relevant baseline outcome, age, sex, current (baseline) participation in other 
self-management programmes, pre-existing cardiovascular disease and duration of diabetes
HeLP-Diabetes Control HeLP-Diabetes vs Control
Baseline
Change from 
baseline to 
12 months Baseline
Change from 
baseline to 
12 months
Mean difference
(95% CI) p Value
Primary outcomes
  HbA1c, (%) 7.3 (0.1) −0.08 (0.07) 7.3 (0.1) 0.16 (0.07) −0.24 (−0.44 to -0.05) 0.014
  HbA1c, mmol/mol 56.3 (1.1) −0.8 (0.8) 56.8 (1.1) 1.8 (0.8) −2.6 (−4.8 to-0.5) 0.014
  PAID 18.2 (1.3) −4.1 (0.9) 19.8 (1.3) −2.5 (0.9) −1.5 (−3.9 to 0.9) 0.209
Secondary outcomes
  Systolic blood pressure, 
mm Hg
134.7 (1.5) −4.2 (1.4) 134.9 (1.5) −0.5 (1.4) −3.8 (−6.6 to -0.9) 0.010
  Diastolic blood pressure, 
mm Hg
77.8 (1.0) −2.5 (0.9) 77.1 (1.0) −1.9 (0.8) −0.6 (−2.4 to 1.2) 0.519
  Body mass index, kg/m2 30.1 (0.5) 0.12 (0.2) 30.0 (0.5) −0.04 (0.2) 0.16 (−0.30 to 0.62) 0.498
  Total cholesterol, mmol/L 4.1 (0.1) −0.08 (0.06) 4.2 (0.1) −0.15 (0.06) 0.07 (−0.09 to 0.2) 0.370
  HDL cholesterol, mmol/L 1.25 (0.03) −0.003 (0.018) 1.26 (0.03) 0.004 (0.018) −0.007 (−0.054 to 0.039) 0.754
  Completion of nine 
essential processes*
65% (3.7) −5.1% 61% (3.8) 3.4% 0.78 (0.45 to 1.35) 0.379
  HADS 9.3 (0.5) −1.05 (0.44) 9.1 (0.5) −0.60 (0.48) −0.45 (−1.68 to 0.78) 0.474
  DMSES† 98.8 (2.4) 2.93 (2.90) 103.6 (2.3) 1.38 (2.79) 1.55 (−5.74 to 8.84) 0.674
  DTSQ 32.2 (0.6) 0.94 (0.57) 32.2 (0.6) 0.45 (0.61) 0.49 (−1.18 to 2.15) 0.564
Results from multiply imputed data shown. Data are mean (SE) or mean difference (95% CI) unless otherwise specified.
*Percentage (SE) and OR (95% CI).
†Linear regression results shown due to lack of convergence for mixed model.
DMSES, Diabetes Management Self-Efficacy Scale; DTSQ, Diabetes Treatment Satisfaction Questionnaire;  HADS, Hospital Anxiety 
and Depression Scale; HbA1c, glycated haemoglobin;  HDL, high-density lipoprotein; HeLP-Diabetes, Healthy Living for People with 
Diabetes; PAID, Problem Areas in Diabetes.
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better control of their diabetes and cardiovascular risk 
factors,6 7 and were much less distressed.21 This finding 
mirrors that of a recent systematic review of demographic 
factors associated with web portal usage among people 
with diabetes which found that those with well controlled 
diabetes were more likely to use such portals than those 
with poor control.37 However, fewer of our participants 
self-rated their computer skills as excellent (57% of our 
sample compared with a national average of 73%).12 This 
good control at baseline has two implications—first, that 
Figure 2 Mean HbA1c (95% CI) over follow-up by randomised group using multiple imputation. HbA1c, glycated haemoglobin; 
HeLP-Diabetes, Healthy Living for People with Diabetes.
Figure 3 Mean PAID score (95% CI) over follow-up by randomised group using multiple imputation. PAID, Problem Areas in 
Diabetes; HeLP-Diabetes, Healthy Living for People with Diabetes.
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there was little room for improvement in this population 
and second, that this population may have been unusu-
ally motivated to self-manage their diabetes. Although 
every effort was made to maintain blinding, it is possible 
that some participants may have discussed their use of 
the intervention with research nurses, making it possible 
to infer which arm they had been allocated to. This 
could have affected research nurses’ measurements of 
secondary clinical outcomes, such as blood pressure or 
weight, but could not have affected assessment of HbA1c 
as this was measured by laboratory staff who were blinded. 
There appeared to be high potential for contamination 
between two participants who shared the same surname 
and address, and a further two participants did not receive 
their allocated intervention due to an error at practice 
level; excluding these four made no difference to the 
results. A further limitation of the trial is that it provides 
little insight into the mechanism of action of HeLP-Dia-
betes. This was the result of a deliberate decision to focus 
on clinically important outcomes and minimise both the 
response burden and the potential impact of measure-
ment on participants.
This is the first UK-based trial of a web-based self-man-
agement programme for people with type 2 diabetes, 
and internationally, the first trial of such a comprehen-
sive intervention that aims to address the three main 
tasks of self-management: emotional, medical and role 
management.19 In the Cochrane review of comput-
er-based self-management interventions for people with 
T2DM, only four of the included studies had follow-up of 
12 months or more.14 Of these, three interventions were 
clinic-based, with participants completing self-assessment 
tools on a touch screen and receiving tailored advice 
during their baseline visit to their diabetes clinician38–40 
and one was a mobile phone-based intervention which 
provided tailored messages in response to participant’s 
results of blood glucose self-monitoring data.41 A more 
recent systematic review of internet delivered diabetes 
self-management identified 2 trials with 12 or more 
months follow-up.42 One trial was on a structured inter-
vention based on a peer-led, group-based, diabetes 
self-management course.43 There were six sessions, with 
each session available for 1 week. Each session required 
participants to make a specific action plan to address a 
problem they were experiencing. Peer facilitators encour-
aged use of the programme. Follow-up was planned at 6 
and 12 months; however, HbA1c data were only available 
at 6 months. The other trial compared two versions of 
a web-based intervention (with and without additional 
social support) to enhanced usual care. The web-based 
intervention was designed using social cognitive theory 
and a social ecological model, with a focus on three main 
behaviours: dietary intake, physical activity and medica-
tion adherence. Users of either web-based intervention 
received motivational phone calls to encourage adher-
ence and development of action plans. Those randomised 
to the enhanced intervention (with additional social 
support) received two additional phone calls and an invi-
tation to attend a group session. There was no difference 
between groups in HbA1c or other biological outcomes 
at 12 months.44 Thus, the results of this trial add signifi-
cantly to the available literature.
On the basis of these results, HeLP-Diabetes may 
be considered as an addition to the current menu of 
self-management support for people with type 2 diabetes, 
and may help increase overall access and uptake. Most 
commissioned services currently focus on newly diag-
nosed patients, leaving clear unmet need for people 
who have had their diabetes for longer, but are looking 
for ways to improve their health. Many patients are not 
ready to engage in self-management early in their illness 
journey,9 but become motivated to do so later, often as 
a result of a change in medication or development of a 
complication.45 The intervention is low cost, and as most 
costs are fixed, irrespective of number of users, is likely 
to be cost-effective, particularly if widely used. A cost-ef-
fectiveness analysis of HeLP-Diabetes will be reported 
separately.
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Table 3 Extent of website usage over 12-month follow-up
HeLP-
Diabetes Control p Value*
N 
missing
No of log-ins 
per person
18.7 (84.0) 4.8 (8.0) 0.0001 0
No pages 
visited per 
log-in
10.5 (6.7) 7.7 (5.0) <0.0001 105†
Time spent in 
each log-in 
(min)‡
12.3 (9.8) 8.2 (8.4) <0.0001 105†
No of days in 
which website 
was accessed 
over follow-up
10.1 (22.9) 3.3 (5.1) <0.0001 0
Mean (SD) unless otherwise specified.
*Wilcoxon rank-sum test.
†105 individuals did not log in after their facilitation visit (42 
intervention, 63 control).
‡Measured as time from first page accessed to last page accessed 
within a log-in session.
HeLP-Diabetes, Healthy Living for People with Diabetes.
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